{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-024812","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.339027+00:00","generated_at":"2026-06-01T02:37:38.683129+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir Pharma CFO Nathan Fuentes resigns; Michelle Yanez appointed CFO","bullets":["CFO Nathan Fuentes resigned June 18, 2024; separation includes $62,500 over 3 months and option extension.","Michelle Yanez, MBA, appointed CFO effective June 18; was part-time Corporate Controller since May 2022.","Yanez also serves as CFO of MIRA Pharmaceuticals (Nasdaq: MIRA); base salary $137,500/yr.","Yanez receives sign-on bonus tied to change of control, discretionary annual bonus, no upfront equity.","Resignation was not based on any disagreement with Company's operations, policies, or practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-024812","json":"https://secwatch.observer/filing/0001493152-24-024812.json","markdown":"https://secwatch.observer/filing/0001493152-24-024812.md","text":"https://secwatch.observer/filing/0001493152-24-024812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/0001493152-24-024812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:37:38.683129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39f6f930a5","claim":"Nathan Fuentes resigned as Chief Financial Officer at Telomir Pharmaceuticals, Inc..","evidence_excerpt":"On June 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the “ Separation Agreement ”) whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes’ employment as a Chief Financial Officer of the Company would end as of June 18, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/0001493152-24-024812-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"9d41b444c0","claim":"Michelle Yanez was appointed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..","evidence_excerpt":"On June 18, 2024, the Board of the Company appointed Michelle Yanez, MBA as the Chief Financial Officer, of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224024812/0001493152-24-024812-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}